No definition available.
Cardiomyopathy due to drugs and other external agents
CARDIOMYOPATHY_DRUGS_OTHER_EXTER_AGENTS
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
70 |
4. Check minimum number of eventsNone |
70 |
5. Include endpointsNone |
70 |
6. Filter based on genotype QC (FinnGen only) |
70 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- C
- First used in FinnGen datafreeze
- DF5
Similar endpoints
↥List of similar endpoints to
Cardiomyopathy due to drugs and other external agents
based on the number of shared cases.
Similar with more cases:
- Cardiomyopathies, Secondary/extrinsic
- Cardiomyopathy (excluding other)
- Cardiomyopathy
- Other heart diseases
- Other heart diseases, wide
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 370 | 194 | 172 |
| Only index persons | 288 | 154 | 134 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.00 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 58.64 | 60.72 | 56.11 |
| Only index persons | 57.79 | 60.94 | 54.16 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 70 | 46 | 24 |
| Unadjusted period prevalence (%) | 0.01 | 0.02 | 0.01 |
| Median age at first event (years) | 60.89 | 57.22 | 67.94 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
No data
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 63
- Matched controls
- 629
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
I42.7
ICD-10 Finland
Cardiomyopathy due to drugs and other external agents
+∞
90.4
63
*
201
Kela drug reimbursment
Chronic cardiac insufficiency
53.6
26.5
31
11
I42.0
ICD-10 Finland
Dilated cardiomyopathy
50.9
23.0
27
9
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
53.8
20.8
24
7
I50.1
ICD-10 Finland
Left ventricular failure
28.4
19.1
26
15
C09AA05
ATC
ramipril; oral
10.7
16.1
39
83
I42.9
ICD-10 Finland
Cardiomyopathy, unspecified
105.0
15.4
16
*
I50.9
ICD-10 Finland
Heart failure, unspecified
12.5
14.8
29
40
C03CA01
ATC
furosemide; systemic
9.2
14.6
39
94
C03DA01
ATC
spironolactone; oral
13.0
14.4
27
34
I50.0
ICD-10 Finland
Congestive heart failure
18.9
13.1
20
15
I47.2
ICD-10 Finland
Ventricular tachycardia
26.1
11.9
16
8
L03AA02
ATC
filgrastim; parenteral
29.3
10.8
14
6
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
7.7
10.7
28
59
C01AA05
ATC
digoxin; systemic
19.0
10.7
16
11
H02AB02
ATC
dexamethasone; systemic
8.6
10.3
24
42
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
6.3
10.1
33
93
XFP20
NOMESCO Finland
Check up of cardiac pacemaker
10.8
9.8
19
24
115
Kela drug reimbursment
Breast cancer
9.9
9.7
20
28
A03FA01
ATC
metoclopramide; systemic, rectal
6.4
9.3
28
70
C07AB07
ATC
bisoprolol; oral
5.2
8.6
46
214
FN1AC
NOMESCO Finland
Angiography of heart and/or coronary arteries
5.7
8.6
29
82
8500/3-C50.9
ICD-O-3
Infiltrating duct carcinoma, NOS, of breast, NOS
11.9
8.3
15
16
Z95.0
ICD-10 Finland
Presence of electronic cardiac devices
12.5
8.0
14
14
PJD52
NOMESCO Finland
Block dissection of axillary lymph nodes
9.5
7.4
15
20
A49.9
ICD-10 Finland
Bacterial infection, unspecified
7.9
7.0
16
26
C83.31
ICD-10 Finland
Diffuse lymphoma with large B cells
45.0
6.9
8
*
L02BA01
ATC
tamoxifen; oral
12.0
6.9
12
12
AN1
HP
Coronary angiography
6.2
6.9
19
41
127
Kela drug reimbursment
Transplant complication
77.4
6.6
7
*
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
20.6
6.5
9
5
FM1DE
NOMESCO Finland
Doppler ultrasound examination of heart
6.8
6.4
16
30
C50.99
ICD-10 Finland
Breast, unspecified
14.5
6.3
10
8
J01MA12
ATC
levofloxacin; systemic
4.6
6.3
24
74
Z45.0
ICD-10 Finland
Adjustment and management of cardiac devices
10.8
6.1
11
12
N02AA05
ATC
oxycodone; systemic
5.0
6.0
20
53
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
19
37
6.68
10.02
3.9
2.5
453.1
166.0
ng/l
1.09
19
31
25
86
3.97
6.57
7.8
3.0
0.8
0.8
mmol/l
0.34
25
80
31
131
3.45
5.91
2.3
2.0
2.9
3.4
mg/l
0.44
25
117
55
339
3.90
5.55
18.6
10.2
4.4
4.0
e9/l
0.56
50
300
42
235
2.97
4.69
3.0
2.5
174.7
90.2
ug/l
1.04
36
213
22
93
2.99
3.99
2.7
2.1
—
—
—
0
0
36
200
2.65
3.87
4.6
2.9
—
—
—
0
0
11
32
3.89
3.49
1.5
1.2
—
—
—
0
0
19
80
2.89
3.43
3.7
2.6
1.9
1.2
e6/l
0.19
12
48
26
133
2.52
3.20
3.8
2.3
—
—
—
0
0
30
165
2.43
3.16
2.5
2.2
136.1
156.8
u/l
0.18
30
154
13
46
3.24
3.11
2.2
1.4
—
—
—
0
0
11
36
3.44
2.95
5.3
8.7
0.5
0.7
%
1.45
11
36
42
275
2.32
2.91
11.3
7.1
1.2
1.2
mmol/l
0.28
35
233
16
68
2.75
2.80
1.9
2.1
—
—
—
0
0
16
68
2.75
2.80
1.8
1.9
—
—
—
0
0
5
7
7.58
2.59
2.8
2.0
—
—
—
0
0
8
22
3.97
2.45
3.9
2.1
—
—
—
0
0
7
17
4.45
2.43
1.4
1.4
—
—
—
0
0
40
270
2.12
2.42
5.3
4.1
—
—
—
0
0
35
228
2.07
2.29
5.7
4.1
35.1
32.0
ng/l
0.09
30
160
10
37
2.99
2.21
4.3
8.6
1.6
1.8
%
—
10
37
6
14
4.58
2.20
2.5
4.3
19.3
66.8
u/ml
—
6
14
7
20
3.77
2.11
2.9
1.8
—
—
—
0
0
8
26
3.34
2.08
3.4
7.1
24.7
25.3
mmol/l
—
8
26
6
16
4.00
1.98
1.8
1.4
—
—
—
0
0
8
29
2.98
1.85
2.1
1.8
—
—
—
0
0
5
12
4.40
1.85
1.2
2.6
3.1
3.9
g/l
—
5
12
6
18
3.54
1.79
1.0
1.2
—
—
—
0
0
6
19
3.35
1.70
2.7
2.1
—
—
—
0
0
6
19
3.35
1.70
2.3
2.1
—
—
—
0
0
5
14
3.76
1.64
1.2
2.6
96.6
93.1
%
—
5
14
5
14
3.76
1.64
2.6
2.1
—
—
—
0
0
12
58
2.29
1.60
9.8
2.6
6.0
5.7
kpa
0.50
12
58
6
23
2.75
1.40
1.3
2.3
—
—
—
0
0
13
71
2.02
1.30
4.3
2.7
3.0
5.2
e6/l
—
5
41
5
19
2.75
1.23
1.6
1.2
—
—
—
0
0
8
38
2.24
1.23
2.5
3.9
4.0
4.6
pmol/l
—
8
33
0
35
0.00
1.19
0.0
1.1
—
—
—
0
0
7
30
2.48
1.16
7.7
2.9
1.1
1.4
%
—
7
30
7
32
2.32
1.12
3.9
2.5
1.0
2.4
mmol/l
—
7
26
7
35
2.11
1.03
4.1
2.4
4.8
5.1
kpa
—
7
29
30
230
1.53
0.92
2.0
2.0
86.7
95.0
pmol/l
0.39
15
107
10
61
1.75
0.73
6.7
3.5
—
—
—
0
0
53
575
0.68
0.61
4.9
4.5
4.8
4.7
mmol/l
0.14
44
525
0
23
0.00
0.59
0.0
2.4
—
—
—
0
0
55
590
0.68
0.54
5.7
5.0
2.8
2.8
mmol/l
0.03
46
536
53
570
0.71
0.50
4.9
4.5
1.4
1.5
mmol/l
1.12
44
514
17
134
1.35
0.42
1.5
1.7
439.9
474.5
pmol/l
0.24
11
108
0
15
0.00
0.42
0.0
1.6
—
—
—
0
0
0
17
0.00
0.41
0.0
1.8
—
1.8
—
0
10
19
155
1.31
0.38
6.7
4.3
0.0
0.0
estimate
—
6
41
52
550
0.79
0.30
6.7
6.0
43.2
40.4
mmol/mol
0.95
44
509
37
400
0.84
0.24
3.5
3.1
110.6
50.5
u/l
0.92
31
371
5
37
1.38
0.24
1.6
2.5
0.1
0.1
e6/l
—
5
37
62
599
1.31
0.23
39.6
16.4
139.1
139.7
mmol/l
0.80
62
581
5
42
1.20
0.22
1.2
1.1
—
157.0
—
0
17
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
8
72
1.13
0.16
19.4
7.9
—
—
—
0
0
37
348
1.13
0.15
2.5
3.2
—
—
—
0
0
62
601
1.28
0.14
39.5
16.4
4.1
4.0
mmol/l
3.50
62
582
30
279
1.13
0.14
5.8
3.9
0.0
0.0
estimate
—
7
43
53
548
0.86
0.14
4.8
4.1
1.6
1.3
mmol/l
1.45
44
494
5
47
1.07
0.09
3.0
1.9
—
—
—
0
0
30
284
1.10
0.09
7.2
5.1
0.0
0.0
estimate
—
7
44
9
102
0.87
0.07
1.7
1.7
—
—
—
0
0
30
289
1.07
0.05
5.8
3.9
0.0
0.0
estimate
—
7
41
11
101
1.11
0.04
1.1
1.3
1.1
14.6
u/ml
—
5
41
57
568
1.02
0.00
5.6
4.6
6.2
5.9
mmol/l
0.63
52
515
22
223
0.98
0.00
6.7
4.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
3.4
—
—
—
0
0
0
5
0.00
0.00
0.0
10.0
—
—
—
0
0
5
50
1.00
0.00
3.2
2.1
—
—
—
0
0
0
5
0.00
0.00
0.0
3.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
62
613
1.10
0.00
41.5
16.7
84.9
75.7
umol/l
1.30
62
613
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
8
87
0.91
0.00
1.5
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
6.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.6
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint CARDIOMYOPATHY_DRUGS_OTHER_EXTER_AGENTS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CARDIOMYOPATHY_DRUGS_OTHER_EXTER_AGENTS | 5.804 [3.29, 10.24] | < 0.001 |
| Birth year | 0.991 [0.98, 1.0] | 0.04 |
During the follow-up period (1.1.1998 — 31.12.2019), 70 out of 160 females with CARDIOMYOPATHY_DRUGS_OTHER_EXTER_AGENTS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CARDIOMYOPATHY_DRUGS_OTHER_EXTER_AGENTS | 4.335 [2.25, 8.34] | < 0.001 |
| Birth year | 0.991 [0.98, 1.0] | 0.118 |
During the follow-up period (1.1.1998 — 31.12.2019), 58 out of 136 males with CARDIOMYOPATHY_DRUGS_OTHER_EXTER_AGENTS died.
Mortality risk
Mortality risk for people of age
years, who have CARDIOMYOPATHY_DRUGS_OTHER_EXTER_AGENTS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.329% | 0.929% |
| 5 | 2.531% | 5.604% |
| 10 | 7.054% | 13.748% |
| 15 | 13.192% | 25.687% |
| 20 | 21.35% | 40.197% |
Relationships between endpoints
↥Index endpoint: CARDIOMYOPATHY_DRUGS_OTHER_EXTER_AGENTS – Cardiomyopathy due to drugs and other external agents
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data